CD4 and rheumatoid arthritis: Similarly, Thurlings and colleagues found no effect of rituximab therapy on PB CD4+ or CD8+ T cells of RA patients [5], whereas Leandro and colleagues reported a decrease only in a small subpopulation of CD3+CD20+ cells while the total CD4+ subset and the activated CD4+ subset remained unaffected [24].